Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data
Advances in Therapy · 2024
DOI: 10.1007/s12325-024-02849-2 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Advances in Therapy, 2024. Verfasst von Antonia Morga und 5 weiteren Autor:innen. Beteiligte Einrichtung: Astellas Pharma Europe Ltd., 300 Dashwood Lang Road, Bourne Business Park, Addlestone, KT15 2NX, UK. antonia_morga@astellas.com. Hauptthemen laut MEDLINE: Hot Flashes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Astellas Pharma US.
Abstract (Originalsprache)
INTRODUCTION: Vasomotor symptoms (VMS), the characteristic symptoms of menopausal transition, are often the primary reason women seek treatment. Current treatment options for VMS include fezolinetant, a nonhormonal, selective neurokinin 3 receptor antagonist. This study aimed to define a clinically meaningful threshold for reduction of moderate-to-severe VMS in postmenopausal women treated with fezolinetant and then apply it in a responder analysis of the pooled trial data. METHODS: This analysis pooled data from two identical phase 3, double-blind, placebo-controlled studies that randomized women with moderate-to-severe VMS to once-daily fezolinetant 30 mg, 45 mg, or placebo (SKYLIGHT 1 and 2). The frequency of VMS was collected daily using an electronic diary. Patients completed the Patient Global Impression of Change in VMS (PGI-C VMS) instrument, which assessed changes in hot flushes/night sweats at weeks 4 and 12 compared with baseline using a seven-point Likert scale. VMS frequency data were anchored to PGI-C VMS data; the anchor level for meaningful within-patient change in PGI-C VMS was "moderately better." RESULTS: In the pooled population (N = 1022), the mean (standard deviation) estimated thresholds for a meaningful within-patient change in moderate-to-severe VMS frequency were - 5.73 (3.47) at week 4 and - 6.20 (5.18) at week 12. Applying the thresholds for meaningful within-patient change to responder analyses ("missing as non-responder" imputation method) indicated a favorable clinical benefit: greater proportions of responders were observed in the fezolinetant 30-mg and 45-mg groups compared with placebo at week 4 (odds ratio range 2.48-2.91; P < 0.001) and week 12 (odds ratio range 1.908-2.68; P < 0.001). CONCLUSION: PGI-C VMS is sensitive to change and correlates with VMS frequency: a reduction of approximately six VMS episodes per day from baseline to week 12 was meaningful at the individual patient level. Fezolinetant provides a meaningful clinical benefit for women with moderate-to-severe VMS associated with menopause and represents an important nonhormonal treatment option. TRIAL REGISTRATION NUMBER: NCT04003155 and NCT04003142.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Astellas Pharma Europe Ltd., 300 Dashwood Lang Road, Bourne Business Park, Addlestone, KT15 2NX, UK. antonia_morga@astellas.com.
- Astellas Pharma GmbH Deutschland, Munich, Germany.
- Astellas Pharma Global Development, Inc., Northbrook, IL, USA.
- Astellas Pharma Europe Ltd., 300 Dashwood Lang Road, Bourne Business Park, Addlestone, KT15 2NX, UK.
- RTI Health Solutions, North Carolina, NC, USA.
ORCID-Profile: Antonia Morga
Förderung
- Astellas Pharma US
Zitieren
APA
Morga, A., Zimmermann, L., Valluri, U., Siddiqui, E., McLeod, L., & Bender, R. H. (2024). Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data. Advances in Therapy. https://doi.org/10.1007/s12325-024-02849-2
Vancouver
Morga A, Zimmermann L, Valluri U, Siddiqui E, McLeod L, Bender RH. Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data. Advances in Therapy. 2024. doi:10.1007/s12325-024-02849-2
BibTeX
@article{Morga2024,
author = {Morga, Antonia and Zimmermann, Lisa and Valluri, Udaya and Siddiqui, Emad and McLeod, Lori and Bender, Randall H},
title = {Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data},
journal = {Advances in Therapy},
year = {2024},
doi = {10.1007/s12325-024-02849-2}
}
EUVIMED